Close Menu

Xagenic

The company expects the funds to accelerate its efforts to develop and commercialize the Xagenic X1 diagnostic platform.

The group has licensed the clamp method, as well as earlier technology developments, to Xagenic, which is working to commercialize it in various diagnostic areas.

Electrochemical clamp assays, developed at the university could expand Xagenic's X1 platform into the liquid biopsy space.

NEW YORK (GenomeWeb) – Decentralized molecular diagnostics firm Xagenic today announced the second closing of its Series B financing round, bringing in a total of C$25.5 million (US$23.8 million).

Linda McAllister has joined Toronto-based molecular diagnostics firm Xagenic as chief medical officer.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Xagenic today announced that it has closed a Series B round of financing that brought in $20 million (US$18.8 million) in funding.

Korean technology and test developer Seegene this week said that it has developed a new, real-time microarray platform that it claims eliminates the "burdensome, time-consuming" steps associated with current array technologies, and is "highly applicable" to point-of-care testing.

A team of researchers at the University of Toronto has developed the next-generation of a chip-based platform for the identification of infection-causing bacteria.

NEW YORK (GenomeWeb News) – Startup molecular diagnostics company Xagenic today announced funding of up to C$990,000 (US$977,495) from the Canadian government in support of its diagnostic platform.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.